Engineered Extracellular Vesicles Modified by Angiopep-2 Peptide Promote Targeted Repair of Spinal Cord Injury and Brain Inflammation
Top Cited Papers
Open Access
- 24 January 2025
- journal article
- research article
- Published by American Chemical Society (ACS) in ACS Nano
- Vol. 19 (4) , 4582-4600
Abstract
Engineered extracellular vesicles play an increasingly important role in the treatment of spinal cord injury. In order to prepare more effective engineered extracellular vesicles, we biologically modified M2 microglia. Angiopep-2 (Ang2) is an oligopeptide that can target the blood-brain barrier. Through single-cell sequencing and immunofluorescence experiments, we confirmed that the expression of LRP-1, the targeted receptor of Ang2, was elevated after spinal cord injury. Subsequently, we integrated the Ang2 peptide segment into M2 microglia to obtain Ang2-EVs, which could successfully target the site of spinal cord injury. However, in order to improve the function of Ang2-EVs, we pretreated M2 microglia with melatonin, which has anti-inflammatory effects, to obtain M-Ang2-EVs. The results of single-nucleus sequencing of the mouse spinal cord verified that neurons and OPCs gradually transformed into subtypes related to nerve repair functions after treatment with M-Ang2-EVs. This is consistent with the sequencing and enrichment analysis of miRNAs contained in M-Ang2-EVs. We further verified through experiments that M-Ang2-EVs can promote microglia/macrophages to phagocytose sphingomyelin, promote axon remyelination and axon elongation, and maintain the integrity of the blood-spinal barrier. Since Ang2 can also target the blood-brain barrier, we found that M-Ang2-EVs can also reduce brain inflammation that results from spinal cord injury. Our study applied the Angiopep-2 peptide to spinal cord injury to enhance the targeting of injured cells, and successfully construct engineered extracellular vesicles that can target the spinal cord injury site and the brain.Keywords
Funding Information
- National Natural Science Foundation of China (82272499)
- Key program of Taizhou Clinical Medical College (TZKY20220302)
This publication has 62 references indexed in Scilit:
- M2 Microglia-derived Exosomes Promote Spinal Cord Injury Recovery in Mice by Alleviating A1 Astrocyte ActivationMolecular Neurobiology, 2024
- Specific anti‐glioma targeted‐delivery strategy of engineered small extracellular vesicles dual‐functionalised by Angiopep‐2 and TAT peptidesJournal of Extracellular Vesicles, 2022
- Engineered extracellular vesicles as brain therapeuticsJournal of Controlled Release, 2021
- Small extracellular vesicles released by infused mesenchymal stromal cells target M2 macrophages and promote TGF‐β upregulation, microvascular stabilization and functional recovery in a rodent model of severe spinal cord injuryJournal of Extracellular Vesicles, 2021
- Extracellular vesicles as drug delivery systems: Why and how?Advanced Drug Delivery Reviews, 2020
- MicroRNAJournal of Allergy and Clinical Immunology, 2018
- Microglia: origins, homeostasis, and roles in myelin repairCurrent Opinion in Neurobiology, 2017
- The blood–spinal cord barrier: Morphology and Clinical ImplicationsAnnals of Neurology, 2011
- Activation of microglia by aggregated β-amyloid or lipopolysaccharide impairs MHC-II expression and renders them cytotoxic whereas IFN-γ and IL-4 render them protectiveMolecular and Cellular Neuroscience, 2005
- Differential regulation of myelin phagocytosis by macrophages/microglia, involvement of target myelin, Fc receptors and activation by intravenous immunoglobulinsJournal of Neuroscience Research, 2002